ALX Oncology finances its clinical research pipelines, laboratory operations, and corporate overhead through a combination of public equity offerings, institutional venture capital backing, upfront payments from strategic research collaborations, and proceeds secured following its initial public offering on the NASDAQ exchange. Managing burn rates and securing secondary capital markets funding remain essential for sustaining its multi-year clinical trial roadmap.